Morgan Stanley Reiterates Equal-Weight on Rhythm Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintained a $28 price target.
August 04, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Rhythm Pharmaceuticals and maintained a $28 price target.
The news is directly about Rhythm Pharmaceuticals. Morgan Stanley's reiteration of an Equal-Weight rating and maintenance of a $28 price target suggests that they believe the stock is fairly valued at its current price. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100